Economists throw doubt on generic drug price advantage over branded version

(Medical Xpress)—People given a choice between generic or branded drugs should look closely at the ingredients in the drug they are buying, argue economists from Deakin University's Graduate School of Business.

In a paper published in the Berkeley Electronic (BE) Journal of Economic Policy and Analysis the researchers (Munirul, Vijay, Aaron and Pasquale) throw doubt on the claims by governments that the introduction of generics really does benefit consumers.

Lead researcher Dr Munirul Nabin said governments generally argued that simplifying the entry process for generic drugs increased competition in the , causing prices to fall.

"However a number of studies have shown that prices of branded drugs actually increases after generic drugs enter a market – an effect economists call the Generic Competition Paradox," he said.

Dr Nabin said theorised there were a number of reasons why the phenomena occurred, including doctors preferring to prescribe branded drugs over generics and doctors referring patients who had didn't have health insurance to generic drugs, however Deakin's analysis based on data from Canada revealed another explanation.

"It is not generic drugs vs branded drugs that is the issue, but whether the generic drugs are therapeutically equivalent to the branded variety that is the factor," he said.

Dr Nabin said put simply both generic and branded drugs had two types of ingredients, active and inactive.

"In Australia and elsewhere the in both the branded and the generic has to be biologically equivalent and there are regulatory criteria around this," he said.

"However the inactive ingredient in the branded and can differ.

"They may have different release mechanisms, dyes, pH adjusters and different salt combinations, all of which affect the stability and performance of the drug and consequently its effect on the patient.

"This nuance is well-known in the but there is a growing body of medical evidence which suggests that just because a drug is biologically equivalent, it does not make it therapeutically equivalent and thus interchangeable."

Dr Nabin said medical researchers had highlighted issues with generics, particularly for patients suffering severe illnesses such as epilepsy and depression.

"Anti-epileptic drugs and some psychotherapeutic drugs exhibit a narrow therapeutic index which makes it difficult for doctors and patients to substitute between the two varieties of drugs," he said.

"Because of this the price of branded drugs is likely to rise after the enter a market, not fall.

"To overcome this governments need to segregate drugs into their drug class when considering the effect of generic entry on price.

"If they don't they may find their health costs go up because the efficacy of the drug is not the same and more money is spent retreating patients as side-effects increase."

More information: www.degruyter.com/view/j/bejea… 4/1935-1682.3234.xml

Related Stories

First generic version of cancer drug Doxil approved

Feb 04, 2013

(HealthDay)—The first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) has been approved by the U.S. Food and Drug Administration, which says the action should help relieve shortages ...

Professor explores generic drug effectiveness

May 27, 2013

(Medical Xpress)—It's likely if you're sick, your doctor is more inclined to prescribe a brand name drug in place of its generic equivalent. Or maybe you would rather pick up some Advil for that headache, instead of the ...

Senators push for quicker generic drug access

Jul 23, 2013

(AP)—Two senators want to do away with the agreements that pharmaceutical companies make with one another to keep lower-priced generic copies of brand-name drugs off the market.

High court weighs drug companies' generics policy

Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.